Diabetic foot ulcers (DFU) are chronic complications due to poor diabetic control. Diabetic foot ulcers can lead to lifelong disability and substantially diminish the quality of life. The aim of this study was to carry out a thorough evaluation of diabetic foot ulcer management, compare current scenario of DFUs care with the International guidelines and to identify the extended roles of clinical pharmacist to improve the conditions of diabetic patient with foot ulcers. It is a retrospective qualitative study carried out in two tertiary care hospitals of Tamil Nadu state. The patients were selected based on inclusion and exclusion criteria admitted in the hospitals with diabetic foot ulcers. The patient's sociodemographic and clinical characteristics tools from the patient medication records (PMR) were collected and taken into considerations for the study. The study revealed that diabetic foot ulcer was more prevalent among male patients with type 2 diabetes since 11 to 25 yrs belongs to the age group between 51-60 years. It was found that 60.5% of the patients having at least one co-morbid condition and 90.6% of patients possess one or more risk factors to develop diabetic foot ulcers. Glycated hemoglobin (HbA 1c ) test were done only by 54.7% of the patients, which showed that it was not insisted as an important identification tool for diabetic foot ulcer. The PMR revealed numerous antibiotics switch-over for the wound treatment as well. From the study it was concluded that an immediate requirement and thorough evaluation of enhanced foot care management, patient centered care and diabetic foot surveillance etc is needed for diabetic foot ulcer management. A comparative current scenario of DFUs care with the International guidelines and its adaptation and modifications according to our need is to be emphasized. Amalgamation of clinical pharmacy services with the multidisciplinary diabetic foot care team services is to be made. The clinical pharmacist's intervention is to be put forward to improve the conditions of diabetic patient with foot ulcers to decrease the alarming incidences in Indian hospital settings.
INTRODUCTION
Diabetes is a group of heterogeneous disorders characterized by hyperglycemia and glucose intolerance due to insulin deficiency, impaired effectiveness of insulin action, or both [1] . About 15%-25% of diabetic patients will develop chronic ulcers of foot or lower extremity during their lifetime [2] [3] [4] .The etiology of foot ulcers is multi-factorial [3, 5] among which peripheral vascular disease, neuropathy and retinopathy are considered to be the most important causative factors [6] . Foot ulcers in diabetic patient are the major sufferings and cost-effective [7] . Diabetic foot ulcer patients use more in and outpatient health resources and
Porselvi et al.
A Retrospective Qualitative Study on DFU Marmara Pharm J 21 /2: 412-418, 2017 this condition is one of the main factors for the hospital admission of diabetic patients [8] .
In India incidence of foot ulcers vary by many socio-cultural practices which include barefoot walking, inadequate facilities for diabetic care, low levels of education and poor socio-economic conditions [9] . HbA 1C measurements are used to test metabolic control in diabetics at least three months, and to assess the risk for complications [10] . Diabetic foot ulcer (DFU) can lead to lifelong disability and may substantially diminish the quality of life in these patients and only two third of these ulcers are expected to heal [11] [12] [13] [14] . The median time taken for the healing of these ulcers is approximately 6 months; up to 28% may result in some form of amputation [15] and the amputee patient's life expectancy was found to be 4.32 years in a study [16] .
If the treatment provided is inadequate that may result in therapeutic complications and unnecessary extension of healing times [17] . A variety of antibiotics ranging from narrow spectrum oral agents to broad spectrum parenteral agents are employed in treating diabetic foot infections. During the recent two decades study there are only a few investigations on antimicrobial therapy defined for the infections [18] . Studies on cost effectiveness of antimicrobials are very limited. The Infectious Society of India (IDSA) guideline recommends deep tissue culture study obtained by biopsy or curettage as study specimen and also suggest avoiding swab specimens, especially from inadequately debrided wounds, as they provide less accurate results.
Foot ulcers are susceptible to infection and poly-microbial infection which may spread rapidly, causing overwhelming tissue destruction. This process is the main reason for major amputation in neuropathic feet. Potential strategies to minimize the sequelae of foot complications includes early recognition of the 'at risk' foot; prompt use of preventative measures; and rapid and intensive treatment of foot complications in multidisciplinary foot care services [19] [20] [21] . Diabetic foot care guidelines considered to be one of the most cost-effective forms of health care expenditures provided that the guideline is goal-focused and properly implemented. International Diabetes Federation (IDF), Diabetes Atlas 7 th edition states that many governments and public health planners are still remain unaware of the current magnitude and more importantly the future potential increase of diabetes cases as well as its serious complication in their own countries. National Institute of Clinical Excellence (NICE) guideline insists patient centered care for foot ulcers with type1 and type 2 diabetes patients, where treatment and care should be taken into account according to the individual needs and preferences. Diabetic foot ulcer management centers have documented reductions in amputation rates up to 50% after coordinating the multidisciplinary efforts and incorporation of evidence-based wound care managements [22] [23] [24] [25] [26] [27] [28] .
Aim
The aim of the study was to carry out a thorough evaluation of current DFU management, compare with international guidelines and to identify clearly the extended roles of the Clinical Pharmacist in the management and prevention of DFU.
Objective
• To identify current diabetic foot ulcer treatment and management modalities.
• To identify and compare essential domains in the DFU management and prevention.
• To identify the extended responsibilities of clinical and community pharmacy services.
• To emphasize and discuss on the implementation of an effective prevention programme and standard practice.
Research design Sample Setting
The retrospective qualitative study based on grounded theory method was conducted in two different tertiary care hospitals in Coimbatore and Chennai located in South India. The study was carried out at two different time periods for a total of 10 months. All procedures performed in the study were in accordance with the ethical standards of the institution and the study required no any formal consent.
Patient selection criteria
The two different study periods were taken, from March 2013 to September 2013 and from December 2015 to February 2016 respectively. and no any patients were repeated in the study. Type1 or type 2 diabetes mellitus patients of any age group, diagnosed with diabetic foot ulcers under medication with the prescribed antibiotics and who fulfilled the inclusion criteria, a total of 97 patients were recruited randomly from inpatient wards from various departments of the tertiary care hospital. The highest numbers of diabetic foot ulcer patients were found in both male and female surgical wards. 86 patients were included in the study and remaining 11 patients were excluded from the study based on the inclusion-exclusion criteria. Exclusion criteria involve nondiabetic patients, patients with cellulitic foot ulcer, diabetic patients with varicosities, patient with vasculitic ulcerations and lower extremity rashes.
Study design and methodology
This study was carried out in three phases. Clinical characteristics of patients correlating with the development of DFU like age wise distribution, duration of diabetes and the length of stay in the hospital was categorized and summarized in Table 3 . DFU incidences based on the age wise analysis revealed that the age between 51-60 years (39.5% of mean age 55.68) were found to be the more vulnerable to develop DFU followed by 61-70 years (31.4%) and 41-50 years (16.3%). There were patients having DFU each, one case from below 30 years and one above 80 years. The patients around 46.16% who developed DFU were found to have diabetes, duration 11-25 years. Unfortunately information on duration of diabetics were missing for 21 (24.4%) of the patients. Patients stay in the hospital was less than a week to a month and a half. Information on frequency of admissions of the same patients or who had visited other clinics was lacking. Patients stayed less than a week were more in numbers and their average stay was found to be 5.03 days. 
DISCUSSION
Risk of poorly controlled glycaemia had a high impact on the development of diabetic foot ulcers. Peripheral vascular disease, diabetic retinopathy and nicotine/cigarette smoking were also considerably found to be important while assessing the risk factors which can worsen the condition of diabetic foot ulcers. Previous studies had proved that there was a positive correlation between the treatment failures and the presence of risk factors. The available data for understanding the management of DFU and complications in the local hospital settings required to be improvised. The patient's past medical history records can be modified with more relevant information. Treating the DFU patients under standardized practices would be more appropriate adopting the International DFU care to bring positive outcomes.
Comparison of the important domains for the effective management and prevention of DFU had been shown in Table 4 . HbA1c was not done to the whole patients; reason being the cost factor, can be made cheaper and lack of guidelines insisting HbA 1C is a mandatory diagnostic test for DFU was observed. Co-morbidities seen in DFU patients can be advised that it would worsen their health and it was found that an increased number of medicines were consumed by the patient.  Referral for management from counseling centers and community pharmacies.
 Research in the field of pharmacotherapeutics; pharmacoepidemiology; pharmacy practice; health economics in diabetes and DFU.
 To evaluate and document the results of research in order to improve all aspects of pharmaceutical care.
 Participate in the formulation of antibiotic policy and its regulations  Develop professional standards and audit procedures.
Limitations of the study
In this retrospective study some of the patient's medical and medications history entry were not made available PMR. The study was carried out with 86 diabetic patients among whom only 3 patients were having type1 diabetes but more or equal numbers of type1 diabetes patients have to be recruited to confirm whether type 2 diabetes patients are also more vulnerable to develop DFU than type 1 diabetes.
Conclusion
An audit must be performed to identify high risk patients of diabetic foot ulcers and suitable preventive programmes can be introduced as per the guidelines. Annual surveillance for all diabetic foot ulcer patients must be conducted in the hospital by the foot care team (podiatrist) organised in the hospital for the management and prevention from prognosis which is highly emphasised by the guidelines. The clinical pharmacist should make an attempt to develop treatment guidelines in collaboration with other health care professionals. A unique system of classifying diabetic foot infections suggested by the guidelines must be followed in the hospital setup for the optimal use of antibiotics. In order to identify accurate organism deep tissue culture rather than pus and swab culture tests could be adopted by the hospitals. Antibiotic guidelines for treating DFU/DFI and recommendation for the same must be brought for both empirical and for the treatment of infections. Initiation of the multidisciplinary team and implementation of clinical pharmacy services in the areas of antibiotic policies and guidelines framing, surveillance for high and low risk patients, and in organising awareness and preventive programs are important for the positive treatment outcome among DFU patients. It can be concluded that it is necessary to classify the DFU patients under anyone of the standard classifying system to assess the risk factors based on which preventive strategies can be drawn.
